TICKERNERD
Menu
CTNMCTNMHealthcare · Biotechnology

CTNM Stock Forecast: Contineum Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$13
+3.53% on the day

The 8 Wall Street analysts covering Contineum Therapeutics, Inc. hold a median 12-month price target of $22 — +66.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 49 of 100 as at 8 Oct 2026 — in the lower half.

Market cap
$478.9M
Ticker Nerd rank
49 / 100
Median analyst target
$22
Analysts covering
8
Revenue$0.0
Operating income−$17.4M
Net income−$15.2M
Free cash flow−$11.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.5%
1M
−17.3%
YTD
+15.3%
1Y
+8.4%
From 52W high
−25.0%
From 52W low
+43.7%
$9
$18
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CTNM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Contineum Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
49 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
79
Growth
65
Volatility
65
Quality
54
Value
53
Size
52
Revisions
47
Accruals
34
Issuance
25

Momentum (79): The shares have been drifting up relative to others.

Issuance (25): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CTNM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CTNM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20$25$30Jan 26Apr 26Jul 26Oct 26CTNMHigh $28Median $22Low $17

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
7 Buy1 Hold0 Sell
Low $17Median $22High $28

The green dot is the last close — the median target sits +66.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
28 Sept 2026Morgan StanleyMaintainsEqual-Weight—
28 Sept 2026Morgan StanleyMaintainsEqual-Weight$18 → $17
15 Sept 2026BairdMaintainsOutperform—
15 Sept 2026BairdMaintainsOutperform$20 → $19
15 Sept 2026Jones TradingMaintainsBuy—
15 Sept 2026Jones TradingMaintainsBuy$26 → $24
31 July 2026RBC CapitalMaintainsOutperform—
31 July 2026RBC CapitalMaintainsOutperform$22 → $23
14 May 2026Morgan StanleyMaintainsEqual-Weight$14 → $16
14 May 2026Morgan StanleyMaintainsEqual-Weight—
6 Mar 2026BairdMaintainsOutperform—
8 Jan 2026Morgan StanleyDowngradeEqual-Weight—
24 Nov 2025BairdMaintainsOutperform—
21 Nov 2025RBC CapitalMaintainsOutperform—
25 Sept 2025Leerink PartnersInitiatesOutperform—
18 Aug 2025Morgan StanleyMaintainsOverweight—
19 May 2025Morgan StanleyMaintainsOverweight—
15 May 2025RBC CapitalReiteratesOutperform—
13 Mar 2025Jones TradingInitiatesBuy—
7 Mar 2025BairdMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CTNM appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CTNM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Contineum Therapeutics, Inc. returned +8.4% against +16.2% for the S&P 500, dividends included.

CTNM vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140Jan 26Apr 26Jul 26Oct 26CTNMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CTNM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

Contineum Therapeutics, Inc. (CTNM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
26.0×

Cheaper than 29% of US stocks

Price / sales
—
Price / book
2.0×

Cheaper than 44% of US stocks

EV / EBITDA
−3.8×

Cheaper than 77% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−28.0%

Higher than 28% of US stocks

Return on assets
−19.2%

Higher than 20% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Contineum Therapeutics, Inc. (CTNM) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Contineum Therapeutics, Inc. has a market value of $478.9M and an enterprise value of $248.9M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$57.6M.

  • Diluted earnings per share, trailing twelve months: $−1.73.

  • Free cash flow in the twelve months to 30 June 2026: −$53.5M.

  • Shares outstanding: 37.6M.

  • Trailing P/E: 26.0×; forward P/E: −6.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Contineum Therapeutics, Inc. employs 51 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Oct 2026

Data provided by Twelve Data

Peers

CTNM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CTNMContineum Therapeutics, Inc.$478.9M
49
NGNENeurogene, Inc.$511.5M
58
MPLTMapLight Therapeutics, Inc.$508.5M
12
PBYIPuma Biotechnology, Inc.$507.4M
92
DRUGBright Minds Biosciences, Inc.$506.1M
44
ALTAltimmune, Inc.$505.3M
30
BLSMBlossomhill Therapeutics, Inc.$517.3M
0

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Contineum Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CTNM news & analysis

Johnson & Johnson Partner Contineum Slides as Depression Drug Fails

Benzinga · 15 Sept 2026negative

Contineum Therapeutics shares fell on Tuesday after disappointing Phase 2 results from a key study of its depression drug, a program developed in partnership with Johnson & Johnson. The trial failure weighed on investor sentiment for the company.

Why it matters — A CTNM watcher would care because the failed Phase 2 depression trial represents a setback for one of the company's key partnered pipeline programs.

Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder

Business Wire · 14 Sept 2026negative

Contineum Therapeutics announced that its MOONLIGHT-1 Phase 2 trial evaluating JNJ-5120/PIPE-307 for major depressive disorder did not achieve its primary efficacy endpoint of improvement in MADRS total score at Day 5 versus placebo.

Why it matters — A missed primary endpoint for a key clinical candidate in Phase 2 represents a significant setback for the company's pipeline.

Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference

Business Wire · 25 Aug 2026neutral

Contineum Therapeutics announced that its management is scheduled to present at the 2026 Morgan Stanley Global Healthcare Conference on Tuesday, September 15th at 5:35 p.m. ET. An audio webcast of the fireside chat will be available in the Investors section of the company's website.

Why it matters — A scheduled conference presentation offers CTNM watchers an opportunity to hear management discuss the company and its pipeline of therapies for inflammatory and fibrotic diseases.

Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones

Business Wire · 30 July 2026neutral

Contineum Therapeutics reported its second-quarter 2026 financial results and affirmed its key clinical development milestones, including the PROPEL-IPF global Phase 2 trial evaluating PIPE-791 for fibrotic diseases.

Why it matters — A CTNM watcher would care because the company reaffirmed its key clinical milestones for PIPE-791, a pipeline candidate in a Phase 2 trial for a disease with significant unmet need.

FAQ

Frequently asked questions about CTNM stock

What is the CTNM stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Contineum Therapeutics, Inc. have a median 12-month price target of $22, with estimates ranging from $17 to $28. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CTNM stock a buy right now?

Of the 8 analysts covering Contineum Therapeutics, Inc., 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Contineum Therapeutics, Inc. 49 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CTNM?

As at 8 Oct 2026, Contineum Therapeutics, Inc. ranks 49 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (79 of 100).

Will CTNM stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +66.9% from the last close, and Ticker Nerd's factor model ranks Contineum Therapeutics, Inc. 49 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CTNM stock forecast for 2030?

No analyst covering Contineum Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CTNM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $17 to $28 over the next 12 months.

How has CTNM stock performed over the past year?

Contineum Therapeutics, Inc. returned +8.4% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Contineum Therapeutics, Inc. do?

Contineum Therapeutics Inc. Class A Common Stock represents ownership in Contineum Therapeutics, a clinical-stage biopharmaceutical company focused on developing oral small-molecule therapies for neuroscience, inflammation, and immunology indications.

What is the latest news on CTNM?

The most recent item we track (Benzinga, 15 Sept 2026): "Johnson & Johnson Partner Contineum Slides as Depression Drug Fails". Contineum Therapeutics shares fell on Tuesday after disappointing Phase 2 results from a key study of its depression drug, a program developed in partnership with Johnson & Johnson. The trial failure weighed on investor sentiment for the company.

Company

About Contineum Therapeutics, Inc.

Contineum Therapeutics Inc. Class A Common Stock represents ownership in Contineum Therapeutics, a clinical-stage biopharmaceutical company focused on developing oral small-molecule therapies for neuroscience, inflammation, and immunology indications. The company’s current pipeline is centered on internally developed drug candidates designed to address conditions with significant unmet medical need, including programs targeting pulmonary fibrosis, chronic pain, depression, and multiple sclerosis. Contineum Therapeutics works at the intersection of drug discovery and clinical development, advancing therapies intended to modulate specific biological pathways relevant to these disease areas. Its business is concentrated on research, development, and advancement of candidate medicines rather than commercial product sales, making the stock closely tied to progress in its clinical and regulatory pipeline. Based in San Diego, California, Contineum Therapeutics plays a specialized role in the biotechnology market as a developer of novel therapies for complex inflammatory and neurological disorders.

CEO Mr. Carmine N. Stengone MBA, MS · 51 employees · United States · https://www.contineum-tx.com